Costs of Diarrheal Disease and the Cost-Effectiveness of a Rotavirus Vaccination Program in Kyrgyzstan

ASU Author/Contributor (non-ASU co-authors, if there are any, appear on document)
Richard Rheingans Ph.D., Department Chair (Creator)
Appalachian State University (ASU )
Web Site:

Abstract: Introduction. We examined the cost-effectiveness of a rotavirus immunization program in Kyrgyzstan, a country eligible for vaccine funding from the GAVI Alliance.Methods. We estimated the burden of rotavirus disease and its economic consequences by using national and international data. A cost-effectiveness analysis was conducted from government and societal perspectives, along with a range of 1-way sensitivity analyses. Results. Rotavirus-related hospitalizations and outpatient visits cost US$580,864 annually, of which $421,658 (73%) is direct medical costs and $159,206 (27%) is nonmedical and indirect costs. With 95% coverage, vaccination could prevent 75% of rotavirus-related hospitalizations and deaths and 56% of outpatient visits and could avert$386,193 (66%) in total costs annually. The medical break-even price at which averted direct medical costs equal vaccination costs is $0.65/dose; the societal break-even price is $1.14/dose for a 2-dose regimen. At the current GAVI Alliance–subsidized vaccine price of $0.60/course, rotavirus vaccination is cost-saving for the government. Vaccination is cost-effective at a vaccine price $9.41/dose, according to the cost-effectiveness standard set by the 2002 World Health Report.Conclusions. Addition of rotavirus vaccines to childhood immunization in Kyrgyzstan could substantially reduce disease burden and associated costs. Vaccination would be cost-effective from the national perspective at a vaccine price $9.41 per dose

Additional Information

Richard D. Rheingans, Elmira T. Flem, Renat Latipov, Zuridin S. Nurmatov, Yiting Xue and Kaliya T. Kasymbekova (2009) "Costs of Diarrheal Disease and the Cost-Effectiveness of a Rotavirus Vaccination Program in Kyrgyzstan" Journal of infectious diseases issue 200 pp.S195-S202 Version of Record Available from
Language: English
Date: 2009

Email this document to